H.C. Wainwright lowered the firm’s price target on Iovance Biotherapeutics to $28 from $38 and keeps a Buy rating on the shares post the Q3 report. The company’s focus remains on achieving lifileucel’s approval in the U.S., the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics reports Q3 EPS 46c, consensus 45c
- Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
- Iovance Biotherapeutics options imply 10.1% move in share price post-earnings
- IOVA Upcoming Earnings Report: What to Expect?
- Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023